NASDAQ · RNA
Healthcare · Biotechnology
$8.00
Up+$0.16 (+2.00%)
Updated Oct 22, 2026, 11:02 PM
SID Score
4.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RNA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 21, 2026
RNA closed at $8.00 after 21 trading sessions, down 3.96% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 21, 2026 | $7.97 | $8.32 | $7.96 | $8.00 | 193.21K |
| Oct 20, 2026 | $7.75 | $8.27 | $7.71 | $7.98 | 289.49K |
| Oct 19, 2026 | $7.68 | $7.87 | $7.49 | $7.61 | 243.91K |
| Oct 16, 2026 | $7.79 | $8.06 | $7.67 | $7.67 | 190.98K |
| Oct 15, 2026 | $7.75 | $7.87 | $7.64 | $7.82 | 131.24K |
| Oct 14, 2026 | $7.75 | $7.935 | $7.54 | $7.68 | 269.49K |
| Oct 13, 2026 | $8.22 | $8.22 | $7.75 | $7.75 | 237.19K |
| Oct 12, 2026 | $8.40 | $8.4815 | $8.21 | $8.21 | 87.4K |
| Oct 9, 2026 | $8.29 | $8.50 | $8.1348 | $8.40 | 208.35K |
| Oct 8, 2026 | $8.15 | $8.325 | $7.965 | $8.26 | 649.31K |
| Oct 7, 2026 | $7.95 | $8.13 | $7.93 | $7.93 | 91.82K |
| Oct 6, 2026 | $8.00 | $8.07 | $7.78 | $7.99 | 411.69K |
| Oct 5, 2026 | $7.83 | $8.105 | $7.63 | $7.97 | 268.29K |
| Oct 2, 2026 | $8.22 | $8.4211 | $7.68 | $7.84 | 533.81K |
| Oct 1, 2026 | $8.30 | $8.44 | $7.96 | $8.14 | 395.72K |
| Sep 30, 2026 | $8.38 | $8.46 | $8.22 | $8.28 | 197.31K |
| Sep 29, 2026 | $8.42 | $8.50 | $8.21 | $8.42 | 158.8K |
| Sep 28, 2026 | $8.21 | $8.515 | $8.05 | $8.42 | 504.92K |
| Sep 25, 2026 | $8.20 | $8.365 | $8.10 | $8.29 | 221.43K |
| Sep 24, 2026 | $8.30 | $8.49 | $8.16 | $8.19 | 355.24K |
| Sep 23, 2026 | $9.22 | $9.31 | $8.29 | $8.33 | 434.52K |
The latest Smart Investors Daily articles mentioning RNA.
Company
Market Activity
Research & News
RNA research
Company profile and research snapshot.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 22, 2026 | Roth Capital | Buy | — |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 18, 2026 | Cantor Fitzgerald | Overweight | — |
| May 15, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Oct 9, 2026
Atrium Therapeutics gets a Hold as key risks include unproven human efficacy and clinical and regulatory uncertainties. Click for more on RNA.
Yahoo · Oct 8, 2026
Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase agreement (the "purchase agreement") with a group of leading institutional investors for a private placement financing (the "private placement"). The private placement is expected to result in aggregate gross proceeds to the Company of approximately $50 m
Benzinga · Oct 8, 2026
Company entered into a securities purchase agreement (the "purchase agreement") with a group of leading institutional investors for a private placement financing (the "private placement"). The private
Yahoo · Sep 21, 2026
Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on September 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RNA.
